Neurobiology of Aging
Volume 29, Issue 10 , Pages 1466-1473 , October 2008

Increasing CSF phospho-tau levels during cognitive decline and progression to dementia

  • Christin Andersson

      Affiliations

    • Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 858 585 483; fax: +46 858 586 465.
    • ,
  • Kaj Blennow

      Affiliations

    • Clinical Neurochemistry Laboratory, Department of Clinical Neuroscience, University of Göteborg, Sweden
    • ,
  • Ove Almkvist

      Affiliations

    • Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden
    • ,
  • Niels Andreasen

      Affiliations

    • Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden
    • ,
  • Peter Engfeldt

      Affiliations

    • Department of Clinical Medicine, Family Medicine Research Centre, Örebro University, Örebro, Sweden
    • ,
  • Sven-Erik Johansson

      Affiliations

    • Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden
    • ,
  • Maria Lindau

      Affiliations

    • Department of Public Health and Caring Sciences/Geriatrics, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Maria Eriksdotter-Jönhagen

      Affiliations

    • Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden

Received 4 December 2006 ,Revised 21 March 2007 ,Accepted 30 March 2007.

References 

  1. Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, Lindau M, et al. Differential CSF biomarker levels in APOE ɛ4 positive and negative patients with memory impairment. Dement Geriatr. Cogn. Disord. 2007;23:87–95
  2. Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson S-E, Eriksdotter-Jönhagen M. Identifying patients at high and low risk of cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic out-patients. Dement. Geriatr. Cogn. Disord. 2006;21:251–259
  3. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid β-amyloid(1–42) in Alzheimer disease. Arch. Neurol. 1999;56:673–680
  4. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 2001;58:373–379
  5. Andreasen N, Vanmechelen E, Van De Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiat. 1998;64:298–305
  6. Arnàiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol. Scand. 2003;179(Suppl.):34–41
  7. Bartfai A, Nyman H, Stegman B. Wechsler Adult Intelligence Scale Revised. WAIS-R Manual. Stockholm, Sweden: Psykologiförlaget; 1994;
  8. Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J. Neural. Transm. 2006;113:339–345
  9. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?. Mol. Chem. Neuropathol. 1995;26:231–245
  10. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.. Brain Res. Bull. 2003;61:235–242
  11. Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med. 2004;256:224–234
  12. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund L-O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ɛ4 during 14 months follow-up. Neurosci. Lett. 1996;214:163–166
  13. Bruscoli M, Lovestone S. Is MCI just early dementia? a systematic review of conversion studies. Int. Psychogeriatr. 2004;16:129–140
  14. Bäckman L, Forsell Y. Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. J. Abnorm. Psychol. 1994;103:361–370
  15. Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ɛ4 allele. Neurology. 2004;62:1990–1995
  16. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging. 2006;27:394–401
  17. Dureman I, Sälde H. Psychometric and Experimental Methods for the Clinical Evaluation of Mental Functioning. Uppsala, Sweden: Almqvist och Wiksell; 1959;
  18. Estévez-González A, Kulisevsky J, Boltes A, Otermin P, Garcia-Sanchez C. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging. Int. J. Geriatr. Psychiat. 2003;18:1021–1028
  19. Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;12:189–198
  20. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234
  21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  22. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 1998;44:17–26
  23. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, et al. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci. Lett. 1999;267:65–68
  24. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea & Febiger; 1983;
  25. Levy JA, Bergeson J, Putnam K, Rosen V, Cohen R, Lalonde F, et al. Context-specific memory and apolipoprotein E (ApoE) ɛ4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. J. Int. Neuropsychol. Soc. 2004;10:362–370
  26. Lezak M. Neuropsychological Assessment. 3 ed.. New York: Oxford University Press; 1995;
  27. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson PW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124
  28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  29. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J. Neural. Transm. 2005;112:933–948
  30. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554
  31. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. J. Biol. Chem. 2006;281:1599–1604
  32. Petersen R, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch. Neurol. 2001;58:1985–1992
  33. Petersen R, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Arch. Neurol. 1999;56:303–308
  34. Schmidt M. Rey Auditory Verbal Learning Test—A Handbook. Los Angeles, CA: Western Psychological Services; 1996;
  35. Shors TJ, Matzel LD. Long-term potentiation: what's learning got to do with it?. Behav. Brain Sci. 1997;20:597–655
  36. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094–2103
  37. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiat. 1999;46:750–755
  38. Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 2000;280:119–122
  39. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000;285:49–52
  40. Visser PJ, Scheltens P, Verhey FRJ. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J. Neurol. Neurosurg. Psychiat. 2005;76:1348–1354
  41. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67:1201–1207
  42. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 2003;339:99–102
  43. Wahlund LO, Pihlstrand E, Eriksdotter-Jönhagen M. Mild cognitive impairment: experience from a memory clinic. Acta Neurol. Scand. 2003;107(Suppl. 179):21–24
  44. Wechsler D. Wechsler Memory Scale-Revised. New York: Psychological Corporation; 1987;
  45. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group of Mild Cognitive Impairment. J. Intern. Med. 2004;256:240–246

PII: S0197-4580(07)00138-8

doi: 10.1016/j.neurobiolaging.2007.03.027

Neurobiology of Aging
Volume 29, Issue 10 , Pages 1466-1473 , October 2008

Article Tools

* Image Usage & Resolution